2022 FDA approvals for Novel Drugs (Depopulation Agenda Plan- New Shots to cover Adverse Events from the Abomination Shot)

https://www.nature.com/articles/d41573-023-00001-3

TD Ministries Rumble Video – https://rumble.com/v25d04d-2022-fda-approvals-for-novel-drugs-depop-agenda-new-shots-to-cover-adverse-.html

Last year the FDA’s Center for Drug Evaluation and Research (CDER) approved 37 novel drugs. This is a drop from the highs of the past 5 years, and brings the rolling 5-year average down to 49 drugs per year. But the 2022 approval number remains above the historic average since 1993, of 34 drugs per year (Figure 1, Table 1).

This document is an alignment to the new drugs and the adverse events from the Pfizer Abomination Shot. The Truth will set you Free!!

Pfizer Adverse Events Doc – insomnia (1 Finding),dermatitis (10 Findings), ocular (5 Findings), retina (7 Findings)Download

**Daridorexant (Quviviq)**

**Idorsia**

**Orexin receptor antagonist**

**Insomnia**

**Abrocitinib (Cibinqo)**

**Pfizer**

**JAK inhibitor**

**Atopic dermatitis**

https://pubmed.ncbi.nlm.nih.gov/32509763/
Tebentafusp (Kimmtrak)a

Immunocore

gp100 peptide–HLA×CD3 bispecific T cell engager

Uveal melanoma

**OCULAR SARCOIDOSIS –** **Sarcoidosis is one of the leading causes of inflammatory eye disease**. **Ocular sarcoidosis can involve any part of the eye and its adnexal tissues,** **and may cause uveitis**, episcleritis/scleritis, eyelid abnormalities, conjunctival granuloma, optic neuropathy, lacrimal gland enlargement and orbital inflammation.

**Faricimab (Vabysmo)a**

**Roche/Genentech**

**VEGF×ANG2 bispecific antibody**

**nAMD and DME**

Pfizer Adverse Events Doc- cold agglutinin (1 Finding), Haemolytic anaemia (5 Findings), eosinophilic (3 Findings), neutrophilic (3 Findings), skin disorders (6 Findings)

**Sutimlimab (Enjaymo)a**

**Bioverativ**

**C1s-targeted mAb**

**RBC transfusion due to haemolysis in CAD**

**Mitapivat (Pyrukynd)**

**Agios**

**Pyruvate kinase activator**

**Haemolytic anaemia due to PK deficiency**

**Pacritinib (Vonjo)**

**CTI Biopharma**

**JAK2 inhibitor**

**Myelofibrosis**

**Ganaxolone (Ztalmy)**

**Marinus**

**GABAA receptor positive allosteric modulator**

**Seizures associated with CDD**

https://www.amjmed.com/article/S0002-9343(17)30986-5/fulltext
**Relatlimab; nivolumab (Opdualag)a**

**Bristol Myers Squibb**

**LAG3-targeted mAb plus PD1-targeted mAb**

**Melanoma**

**Relatlimab; nivolumab (Opdualag)**^a
**Bristol Myers Squibb**
**LAG3-targeted mAb plus PD1-targeted mAb**
**Melanoma**

Pfizer Adverse Events Doc- Reactive capillary endothelial proliferation (1 Finding), colitis ulcerative (1 Finding), cardiomyopathy (2 Findings), gastritis (5 Findings), diabetes (6 Findings)

https://www.auajournals.org/doi/10.1016/S0022-5347%2801%2964774-8
**Lutetium Lu-177 vipivotide tetraxetan (Pluvicto)**

**Novartis**

**PSMA-binding radioligand therapeutic agent**

**PSMA-positive prostate cancer**

**Oteseconazole (Vivjoa)**

**Mycovia**

**Azole antifungal**

**Vulvovaginal candidiasis**

**Mavacamten (Camzyos)**
**Bristol Myers Squibb**
**Cardiac myosin inhibitor**
**Classes of obstructive HCM**

**Vonoprazan; amoxicillin; clarithromycin (Voquezna triple pak)**

**Phathom**

**Potassium-competitive acid blocker, plus a penicillin class antibacterial, plus a macrolide antimicrobial**

**Helicobacter pylori infection**

**Tirzepatide (Mounjaro)**
**Eli Lilly & Co.**
**GIP receptor and GLP1 receptor agonist**
**Type 2 diabetes**

Pfizer Adverse Events Doc- psoriasis (2 Findings), amyloidosis (12 Findings), Haemophagocytic
lymphohistiocytosis (1 Finding), facial paralysis (8 Findings)

**Tapinarof (Vtama)**

**Dermavant**

**Aryl hydrocarbon receptor agonist**

**Plaque psoriasis**

**Spesolimab (Spevigo)a**

**Boehringer Ingelheim**

**IL-36R-targeted mAb**

**Generalized pustular psoriasis flares**

**Vutrisiran (Amvuttra)**

**Alnylam**

**TTR-targeted siRNA**

**Polyneuropathy of hereditary TTR-mediated amyloidosis**

**Olipudase alfa (Xenpozyme)a**

**Sanofi/Genzyme**

**Acid sphingomyelinase ERT**

**Acid sphingomyelinase deficiency**

**Daxibotulinumtoxina (Daxxify)a**

**Revance**

**Botulinum toxin**

**Glabellar lines**

Pfizer Adverse Events Doc- psoriasis (2 Findings), blood and lymphatic disorders (1 Finding), hepato (5 Findings), Granul (9 Findings)

**Deucravacitinib (Sotyktu)**

**Bristol Myers Squibb**

**TYK2 inhibitor**

**Plaque psoriasis**

**Eflapegrastim (Rolvedon)a**

**Spectrum**

**Leukocyte growth factor**

**Incidence of infection in non-myeloid malignancies, with myelosuppressive drugs**

**Terlipressin (Terlivaz)**

**Mallinckrodt**

**Vasopressin receptor agonist**

**Kidney function in hepatorenal syndrome**

**Gadopiclenol (Elucirem)**

**Guerbet**

**Gadolinium-based contrast agent**

**Lesions with abnormal vascularity**

Pfizer Adverse Events Doc- retinitis pigmentosa (1 Finding), sclerosis (16 Findings), hepatic (32 Findings), hepato (5 Findings), myelitis (15 Findings)

**Omidenepag isopropyl (Omlonti)**
**Santen**
**Prostaglandin E2 receptor agonist**
**Intraocular pressure in open-angle glaucoma or ocular hypertension**

**Sodium phenylbutyrate; taurursodiol (Relyvrio)**
**Amylyx**
**Mechanism unknown**
**Amyotrophic lateral sclerosis**

**MARBURG’S VARIANT MULTIPLE SCLEROSIS**
**Sodium phenylbutyrate; taurursodiol (Relyvrio)**

**Amylyx**

**Mechanism unknown**

**Amyotrophic lateral sclerosis**

**Futibatinib (Lytgobi)**
**Taiho Oncology**
**FGFR kinase inhibitor**
**FGFR2-aberrant intrahepatic cholangiocarcinoma**
**Tremelimumab (Imjudo)^a**
**AstraZeneca**
**CTLA4-targeted mAb**
**Hepatocellular carcinoma**

**Teclistamab (Tecvayli)**^a
**J&J**
**BCMA×CD3 bispecific antibody**
**Multiple myeloma**

**Acute disseminated encephalomyelitis**
**Teclistamab (Tecvayli)a**

**J&J**

**BCMA×CD3 bispecific antibody**

**Multiple myeloma**

Pfizer Adverse Events Doc- ovarian vein thrombosis (1 Finding), diabetes (6 Findings), myel (27 Findings), lung (5 Findings), autoimmune (45 Findings), lymphatic disorders (1 Finding)

**Mirvetuximab soravtansine (Elahere)a**

**Immunogen**

**FRα-targeted antibody–drug conjugate**

**Ovarian cancer**

**Teplizumab (Tzield)a**

**Provention Bio**

**CD3-targeted antibody**

**Delay onset of type 1 diabetes**

**Olutasidenib (Rezlidhia)**
**Rigel/Forma**
**IDH1 inhibitor**
***IDH1*-mutated AML**

**Myeltis Transverse** **and More with Myel Prefix disease**
**Olutasidenib (Rezlidhia)**
**Rigel/Forma**
**IDH1 inhibitor**
***IDH1*-mutated AML**

**Adagrasib (Krazati)**
**Mirati**
**KRAS-G12C inhibitor**
***KRAS*^G12C-mutated NSCLC**

**Autoimmune Lung Disease**
**Adagrasib (Krazati)**
**Mirati**
**KRAS-G12C inhibitor**
***KRAS*^G12C-mutated NSCLC**

**Moderna jab patents** https://www.modernatx.com/patents open these patents in a browser with a search feature or download and open in an app with a search feature and search things like Hela Cells (Immortal Cancer Cells) Triple Helix, ATCG to ATCCCG (666), Thrombin (Snake Venom), PVA (Quantom Dot),Luciferase, Chimera (MultipleDNA Combos), cDNA (SupremeCourt Ruling to own you), Crispr (DNA Slicing), Prions (Poison),**HIV, HEK293 (aborted fetal tissue), programmable nanoparticles, self-assembled**… you will find them all in there.
**Lenacapavir (Sunlenca)**
**Gilead**
**HIV-1 capsid inhibitor**
**HIV-1 infection**

**Lenacapavir (Sunlenca)**

**Gilead**

**HIV-1 capsid inhibitor**

**HIV-1 infection**

**Mosunetuzumab (Lunsumio)**^a
**Roche/Genentech**
**CD20×CD3 bispecific antibody**
**Follicular lymphoma**

Pfizer Adverse Events Doc- lung (5 Findings), sclerosis (16 Findings), tissue (6 Findings)

**Xe 129 hyperpolarized (Xenoview)**

**Polarean**

**Hyperpolarized contrast agent**

**MRI-evaluation of lung ventilation**

**Ublituximab (Briumvi)**^a
**TG Therapeutics**
**CD20-targeted mAb**
**Relapsing forms of multiple sclerosis**

**Multiple Sclerosis Relapse**
**Ublituximab (Briumvi)a**

**TG Therapeutics**

**CD20-targeted mAb**

**Relapsing forms of multiple sclerosis**

**Anacaulase (Nexobrid)**^a
**Mediwound**
**Proteolytic enzymes from pineapple plants**
**Eschar removal after thermal burns**

**Skin and subcutaneous tissue disorders**
**Anacaulase (Nexobrid)a**

**Mediwound**

**Proteolytic enzymes from pineapple plants**

**Eschar removal after thermal burns**

Approvals by the Center for Biologics Evaluation and Research (CBER) — which regulates vaccines, cell and gene therapies, and blood products — bump the number higher, and underline the uptick in gene therapy submissions (Table 2). Two novel products secured Emergency Use Authorizations, an expedited regulatory pathway that rose to prominence during COVID-19 but that is now seeing less use (Table 3).

Pfizer Adverse Events Doc – Covid-19 (30 Findings), myelitis (15 Findings), measles (1 Finding),

**Covid-19 vaccine, mRNA (Spikevax)**
**Moderna**
**mRNA vaccine**
**COVID-19 immunization**

**Covid-19 Pneumonia**
**Covid-19 vaccine, mRNA (Spikevax)**

**Moderna**

**mRNA vaccine**

**COVID-19 immunization**

**Ciltacabtagene autoleucel (Carvykti)**

**Legend Biotech/J&J**

**BCMA-targeted genetically modified autologous T cell immunotherapy**

**Multiple myeloma**

**Measles, mumps and rubella vaccine live (Priorix)**

**GSK**

**Live, attenuated vaccine**

**Measles, mumps and rubella vaccination**

Pfizer Adverse Events Doc- Blood (14 Findings), neurological (2 Findings), meningitis (9 Findings), colitis (12 Findings), cystitis (2 Findings)

**Betibeglogene autotemcel (Zynteglo)**

**bluebird bio**

**β-globin-encoding lentiviral vector for autologous** **haematopoietic stem cell gene therapy**

**β-thalassemia**
**Etranacogene dezaparvovec (Hemgenix)**

**CSL Behring**

**Factor IX-encoding adeno-associated virus vector gene therapy**

**Haemophilia B**

**Blood and Lymphatic Disorders**
**Betibeglogene autotemcel (Zynteglo)**

**bluebird bio**

**β-globin-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy**

**β-thalassemia**
**Etranacogene dezaparvovec (Hemgenix)**

**CSL Behring**

**Factor IX-encoding adeno-associated virus vector gene therapy**

**Haemophilia B**

**Elivaldogene autotemcel (Skysona)**

**bluebird bio**

**ABCD1-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy**

**Neurologic dysfunction in CALD**

**Fecal microbiota, live (Rebyota)**

**Rebiotix/Ferring**

**Fecal microbiota suspension for rectal enema**

**Recurrence of Clostridioides difficile infection**

**Nadofaragene firadenovec (Adstiladrin)**

**Ferring**

**Interferon α-2b-encoding adenovirus vector gene therapy**

**BCG-unresponsive non-muscle invasive bladder cancer**

Pfizer Adverse Events Doc- Covid-19 (30 Findings) Specifically Covid-19 Pneumonia

**Novavax COVID-19 vaccine, adjuvanted**

**Novavax**

**Subunit vaccine, adjuvanted**

**COVID-19 prevention**

**Bebtelovimaba**

**Eli Lilly & Co.**

**Spike-targeted mAb**

**Mild-to-moderate COVID-19**

The Depopulation Agenda Plan is commencing..

Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.

#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ

	Jan 21, 2022 –… on The Dove Release of Noah symbo…
	Jan 20, 2023 –… on The Dove Release of Noah symbo…
	Jan 19, 2023 –… on The Dove Release of Noah symbo…
	Jan 18, 2023 –… on The Dove Release of Noah symbo…
	WHO announces plans… on WHO issues warning on tubercul…

	Jan 21, 2022 –… on The Dove Release of Noah symbo…
	Jan 20, 2023 –… on The Dove Release of Noah symbo…
	Jan 19, 2023 –… on The Dove Release of Noah symbo…
	Jan 18, 2023 –… on The Dove Release of Noah symbo…
	WHO announces plans… on WHO issues warning on tubercul…

2022 FDA approvals for Novel Drugs (Depopulation Agenda Plan- New Shots to cover Adverse Events from the Abomination Shot)

Like this:

Related

Leave a Reply Cancel reply

Share this:

Like this:

Related

Leave a Reply Cancel reply